A detailed history of New Edge Advisors, LLC transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, New Edge Advisors, LLC holds 45 shares of ADPT stock, worth $251. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45
Previous 45 -0.0%
Holding current value
$251
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$2.88 - $4.8 $28,800 - $48,000
-10,000 Reduced 99.55%
45 $0
Q4 2023

Feb 13, 2024

SELL
$3.46 - $5.33 $48 - $74
-14 Reduced 0.14%
10,045 $49,000
Q2 2023

Aug 14, 2023

SELL
$6.19 - $8.78 $13,438 - $19,061
-2,171 Reduced 17.75%
10,059 $67,000
Q1 2023

May 12, 2023

BUY
$7.8 - $10.11 $78,249 - $101,423
10,032 Added 456.41%
12,230 $107,000
Q4 2022

Feb 14, 2023

BUY
$6.26 - $9.34 $13,759 - $20,529
2,198 New
2,198 $16,000

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $797M
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.